March 1, 2023
AstraZeneca said on February 28 that it submitted a new drug application on the same day for nirsevimab, an anti-respiratory syncytial virus (RSV) human monoclonal antibody developed in collaboration with Sanofi. Nirsevimab is a single dose long-acting antibody that utilizes...read more